Floatz logo

Vocimagene Amiretrorepvec

IDH1 Mutated Solid Tumors

Tocagen Inc.gene_therapyPhase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
21/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the IDH1 Mutated Solid Tumors cohort.

Asset / SponsorPhaseRating
5-FLUOROCYTOSINE
Tocagen Inc.
Phase 1C
5-FC
Tocagen Inc.
Phase 1D

Same molecule, other indications

Vocimagene Amiretrorepvec is also rated in:

anaplastic astrocytomaDormant
CCC
Indicative ·
48 / 100
View asset →
glioblastomaDormant
CCC
Indicative ·
48 / 100
View asset →
anaplastic oligodendrogliomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →